GlassScriptPhysician profile
Ana Idelca Sarante
NPI 1780790253
$8,361.73
in general payments reported to CMS, 2019-2025
38 companies · $1,527 in 2025
The $1,527 reported for 2025 was more than what 90% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $868 · 2020: $839 · 2021: $1,151 · 2022: $1,339 · 2023: $1,212 · 2024: $1,425 · 2025: $1,527.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,164.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,238.15 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $876.43 | 2019-2025 | Repatha, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $807.08 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $799.60 | 2021-2025 | Ubrelvy, Synthroid, Vraylar |
| Pfizer INC. | $728.47 | 2019-2025 | |
| Lilly USA, LLC | $640.75 | 2020-2025 | Zepbound, Mounjaro, Jardiance |
| Glaxosmithkline, LLC. | $509.35 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $505.70 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $472.11 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Amarin Pharma, INC. | $202.80 | 2020-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.11 | 2021-2025 | |
| Esperion Therapeutics, INC. | $167.63 | 2021-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $141.99 | 2019-2025 | Xifaxan |
| Sumitomo Pharma America, INC. | $113.84 | 2023-2025 | Gemtesa |
| Eisai INC. | $98.16 | 2020-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Sarante listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.